MARKET

ARRY

Array Biopharma
ARRY
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
153.99
6.68
16.23
6,121,133,309.40
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Array Technologies Is Maintained at Neutral by Credit Suisse
Dow Jones · 14h ago
DJ Array Technologies Price Target Raised to $42.00/Share From $37.00 by Credit Suisse
Dow Jones · 14h ago
Credit Suisse Maintains Neutral on Array Technologies, Raises Price Target to $42
Credit Suisse analyst Michael Weinstein maintains Array Technologies (NASDAQ:ARRY) with a Neutral and raises the price target from $37 to $42.
Benzinga · 14h ago
Analyst Actions: Johnson Rice Starts Array Technologies at Accumulate with $57 Price Target
MT Newswires · 18h ago
Analyst Actions: Credit Suisse Adjusts Array Technologies' Price Target to $42 from $37, Keeps Neutral Rating
MT Newswires · 19h ago
Array Technologies wins bullish initiation at Piper
Array Technologies (ARRY) +4% pre-market as Piper Sandler initiates coverage of the renewable energy equipment maker with an Overweight rating and Street-high $60 price target, citing the company's capital light business
Seekingalpha · 01/08 13:30
Enphase, SolarEdge continue to climb but Susquehanna cuts on valuation
Solar stocks continue to show impressive strength following Tuesday's Georgia elections that clinched a working U.S. Senate majority for Democrats: [[SOL]] +19.4%, [[MAXN]] +8.5%, [[RUN]] +6.5%, [[SPWR]] +5%, [[NOVA]] +4.7%,[[DQ]]
Seekingalpha · 01/07 15:36
Bloom Energy -12% as J.P. Morgan downgrades on valuation
Bloom Energy ([[BE]] -12.1%) surrenders a chuck of recent gains that had lifted shares to a two-year high, as J.P. Morgan downgrades the company to Neutral from Overweight while raising
Seekingalpha · 12/09/2020 16:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARRY. Analyze the recent business situations of Array Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARRY stock price target is 44.29 with a high estimate of 48.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 282
Institutional Holdings: 225.98M
% Owned: 101.91%
Shares Outstanding: 126.99M
TypeInstitutionsShares
Increased
101
22.89M
New
62
16.02M
Decreased
74
24.33M
Sold Out
27
2.55M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Renewable Energy Equipment & Services
-1.49%
Renewable Energy
-1.46%
Key Executives
Chairman/Independent Director
Carrie Cox
President
John Wattsun
Chief Executive Officer/Director
Ron Squarer
Chief Financial Officer
Jason Haddock
Chief Operating Officer
Andrew Robbins
Chief Scientific Officer
Nicholas Saccomano
General Counsel
Rogan Nunn
Other
Victor Sandor
Independent Director
Charles Baum
Independent Director
Gwendolyn Fyfe
Independent Director
Kyle Lefkoff
Independent Director
John Orwin
Independent Director
Shalini Sharp
Independent Director
Gil Van Lunsen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now

Webull offers kinds of Array Biopharma stock information, including NASDAQ:ARRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARRY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARRY stock methods without spending real money on the virtual paper trading platform.